Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107508 | 0.70 | GAA (0.36) | GAAMAPT | |
| SCHEMBL1384491 | 0.65 | GAA (0.32) | GAAMAPT | |
| SCHEMBL5082196 | 0.65 | GRK6 (0.31) | — | |
| SCHEMBL5612975 | 0.65 | GAA (0.41) | GAAMAPT | |
| SCHEMBL211612 | 0.65 | GAA (0.36) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL3772181 | 0.64 | GAA (0.34) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL2360762 | 0.64 | GAA (0.34) | GAAMAPT | |
| SCHEMBL29157769 | 0.64 | GAA (0.34) | GAAMAPT | |
| SCHEMBL208462 | 0.64 | GAA (0.44) | GAAMAPT | |
| SCHEMBL28157348 | 0.64 | GAA (0.34) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337639-A1 | NAMPT INHIBITORS AND USES THEREOF | Remedy Plan, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2022241257-A1 | NAMPT INHBITORS AND USES THEREOF | REMEDY PLAN, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| CN-102264703-B | mesylate salt of 5- (2- { [6- (2, 2-difluoro-2-phenylethoxy) hexyl ] amino } -1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one as agonist of beta 2 adrenoceptor | ALMIRALL SA | 2014-07-30 | — | — | CN | claimed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | claimed |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024145281-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-04 | — | — | WO | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010118155-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118159-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| CN-101490003-A | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| CN-1652822-A | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | ALTANA PHARMA AG (DE) | 2005-08-10 | — | — | CN | disclosed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | CPT1B, IGF2BP2, IGF2BP3 | GAA 704/4885MAPT 4157/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | GAA 673/4885MAPT 506/4885 |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | VIP, DNPEP, PREP | GAA 109/4885MAPT 3367/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GAA 889/4885MAPT 2749/4885 |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | CRBN, PSMA6, PSMA3 | GAA 276/4885MAPT 2350/4885 |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | GAA 846/4885MAPT 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.